Drugs Made In Stock Performance
| DMAA Stock | 10.29 0.01 0.1% |
Drugs Made has a performance score of 4 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0457, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Drugs Made are expected to decrease at a much lower rate. During the bear market, Drugs Made is likely to outperform the market. Drugs Made In right now shows a risk of 0.18%. Please confirm Drugs Made In potential upside, skewness, and the relationship between the maximum drawdown and semi variance , to decide if Drugs Made In will be following its price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Drugs Made In are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Drugs Made is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.0973 | Five Day Return 0.19 | Year To Date Return 3.31 | Ten Year Return 3.31 | All Time Return 3.31 |
1 | CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles Heres What Happened - Stocktwits | 09/05/2025 |
2 | US Reportedly Plans to Tighten Grip around US Pharma Firms Licensing from CN Drug Firms HK-listed Pharmas Tumble - AASTOCKS.com | 09/10/2025 |
3 | Short Squeeze How does Drugs Made In America Acquisition Corp Equity Right correlate with Nasdaq - July 2025 Trends Weekly Top Performers Watchlists - | 09/18/2025 |
4 | Tylenol producer sees stock rebound - Northwest Arkansas Democrat-Gazette | 09/24/2025 |
5 | Pfizer stock jumps 14 percent as TrumpRx drug pricing deal eases tariff fears - drugdiscoverytrends.com | 10/01/2025 |
6 | Amgen Stock Falls as It Cuts 60 percent Off Cholesterol Drug Price, Heeding Trumps Clamor - TipRanks | 10/06/2025 |
7 | Protagonist Therapeutics Stock Surges on Drug Success - TipRanks | 10/10/2025 |
Drugs Made Relative Risk vs. Return Landscape
If you would invest 1,022 in Drugs Made In on July 14, 2025 and sell it today you would earn a total of 7.00 from holding Drugs Made In or generate 0.68% return on investment over 90 days. Drugs Made In is currently generating 0.0107% in daily expected returns and assumes 0.1798% risk (volatility on return distribution) over the 90 days horizon. In different words, 1% of stocks are less volatile than Drugs, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Drugs Made Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Drugs Made's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Drugs Made In, and traders can use it to determine the average amount a Drugs Made's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0593
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DMAA |
Estimated Market Risk
| 0.18 actual daily | 1 99% of assets are more volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Drugs Made is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Drugs Made by adding it to a well-diversified portfolio.
Drugs Made Fundamentals Growth
Drugs Stock prices reflect investors' perceptions of the future prospects and financial health of Drugs Made, and Drugs Made fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Drugs Stock performance.
| Current Valuation | 342.94 M | ||||
| Shares Outstanding | 33.52 M | ||||
| Book Value Per Share | (0.21) X | ||||
| Market Capitalization | 343.37 M |
About Drugs Made Performance
By analyzing Drugs Made's fundamental ratios, stakeholders can gain valuable insights into Drugs Made's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Drugs Made has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Drugs Made has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | 1.76 | 1.57 | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | 1.77 | 1.57 |
Things to note about Drugs Made In performance evaluation
Checking the ongoing alerts about Drugs Made for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Drugs Made In help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Drugs Made In has a very weak financial position based on the latest SEC disclosures | |
| About 27.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Protagonist Therapeutics Stock Surges on Drug Success - TipRanks |
- Analyzing Drugs Made's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Drugs Made's stock is overvalued or undervalued compared to its peers.
- Examining Drugs Made's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Drugs Made's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Drugs Made's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Drugs Made's stock. These opinions can provide insight into Drugs Made's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Drugs Stock analysis
When running Drugs Made's price analysis, check to measure Drugs Made's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Drugs Made is operating at the current time. Most of Drugs Made's value examination focuses on studying past and present price action to predict the probability of Drugs Made's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Drugs Made's price. Additionally, you may evaluate how the addition of Drugs Made to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |